Literature DB >> 9881533

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria.

E S Roach1, M R Gomez, H Northrup.   

Abstract

At the recent tuberous sclerosis complex consensus conference, the clinical diagnostic criteria for tuberous sclerosis complex were simplified and revised to reflect both new clinical information about tuberous sclerosis complex and an improved understanding of the disorder derived from molecular genetic studies. Based on this new information, some clinical signs once regarded as pathognomonic for tuberous sclerosis complex are now known to be less specific. No single sign is present in all affected patients, and there is no proof that any single clinical or radiographic sign is absolutely specific for tuberous sclerosis complex. Accordingly, the clinical and radiographic features of tuberous sclerosis complex have now been divided into major and minor categories based on the apparent degree of specificity for tuberous sclerosis complex of each feature. A definitive diagnosis of tuberous sclerosis complex now requires two or more distinct types of lesions, rather than multiple lesions of the same type in the same organ system. Although diagnosis on purely clinical grounds can continue to be difficult in a few patients, there should be little doubt about the diagnosis for those individuals who fulfill these strict criteria. Couples with more than one child with tuberous sclerosis complex, no extended family history, and no clinical features of tuberous sclerosis complex are more likely to have germline mosaicism for tuberous sclerosis than nonexpression of the mutation. Germline mosaicism, while fortunately rare, will not be suspected from either diagnostic criteria or molecular testing until a couple has multiple affected children. Genetic counseling for families with one affected child should include a small (1% to 2%) possibility of recurrence, even for parents who have no evidence of tuberous sclerosis complex after a thorough diagnostic evaluation.

Entities:  

Mesh:

Year:  1998        PMID: 9881533     DOI: 10.1177/088307389801301206

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  187 in total

1.  Complete inactivation of the TSC2 gene leads to formation of hamartomas.

Authors:  K S Au; A A Hebert; E S Roach; H Northrup
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  Loss of white matter microstructural integrity is associated with adverse neurological outcome in tuberous sclerosis complex.

Authors:  Jurriaan M Peters; Mustafa Sahin; Vanessa K Vogel-Farley; Shafali S Jeste; Charles A Nelson; Matthew C Gregas; Sanjay P Prabhu; Benoit Scherrer; Simon K Warfield
Journal:  Acad Radiol       Date:  2012-01       Impact factor: 3.173

3.  Echocardiographic screening results in patients with tuberous sclerosis complex.

Authors:  Miraude E A P M Adriaensen; Maarten J M Cramer; Madelon E E Brouha; Cornelia M Schaefer-Prokop; Mathias Prokop; Pieter A F M Doevendans; Bernard A Zonnenberg; Harm H H Feringa
Journal:  Tex Heart Inst J       Date:  2010

Review 4.  Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex.

Authors:  Petrus J de Vries
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 5.  Neurocutaneous Disorders for the Practicing Neurologist: a Focused Review.

Authors:  Anna Carolina Paiva Costa T Figueiredo; Nikolas Mata-Machado; Matthew McCoyd; José Biller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

6.  CT of sclerotic bone lesions: imaging features differentiating tuberous sclerosis complex with lymphangioleiomyomatosis from sporadic lymphangioleiomymatosis.

Authors:  Nilo A Avila; Andrew J Dwyer; Antoinette Rabel; Thomas Darling; Chien-Hui Hong; Joel Moss
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

Review 7.  Consensus clinical guidelines for the assessment of cognitive and behavioural problems in Tuberous Sclerosis.

Authors:  Petrus de Vries; Ayla Humphrey; Deborah McCartney; Penny Prather; Patrick Bolton; Ann Hunt
Journal:  Eur Child Adolesc Psychiatry       Date:  2005-07       Impact factor: 4.785

8.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.

Authors:  Darcy A Krueger; Marguerite M Care; Karen Agricola; Cindy Tudor; Maxwell Mays; David Neal Franz
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

9.  Diffuse cerebral language representation in tuberous sclerosis complex.

Authors:  Anne Gallagher; Naoaki Tanaka; Nao Suzuki; Hesheng Liu; Elizabeth A Thiele; Steven M Stufflebeam
Journal:  Epilepsy Res       Date:  2012-10-23       Impact factor: 3.045

Review 10.  Thoracoabdominal imaging of tuberous sclerosis.

Authors:  Cara E Morin; Nicholas P Morin; David N Franz; Darcy A Krueger; Andrew T Trout; Alexander J Towbin
Journal:  Pediatr Radiol       Date:  2018-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.